Our results suggest a promising strategy would be to use ADAR1i-124 in combination with DNMTi or even other epigenetic inhibitors known to reactivate dormant ERVs20,48,49 for treating cancers that are less responsive to ADAR1 inhibitor monotherapy. This evidence concerns the gene ADAR and cancer.